BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 16581111)

  • 1. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.
    Lev EI; Patel RT; Guthikonda S; Lopez D; Bray PF; Kleiman NS
    Thromb Res; 2007; 119(3):355-60. PubMed ID: 16581111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
    Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
    Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
    Lepäntalo A; Virtanen KS; Heikkilä J; Wartiovaara U; Lassila R
    Eur Heart J; 2004 Mar; 25(6):476-83. PubMed ID: 15039127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
    Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
    Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.
    Staritz P; Kurz K; Stoll M; Giannitsis E; Katus HA; Ivandic BT
    Int J Cardiol; 2009 Apr; 133(3):341-5. PubMed ID: 18485500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
    Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G
    Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
    Dropinski J; Jakiela B; Sanak M; Wegrzyn W; Biernat M; Dziedzina S; Plutecka H; Szczeklik A
    Thromb Haemost; 2007 Jul; 98(1):201-9. PubMed ID: 17598014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
    Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
    Storey RF; Melissa Thornton S; Lawrance R; Husted S; Wickens M; Emanuelsson H; Cannon CP; Heptinstall S; Armstrong M
    Platelets; 2009 Aug; 20(5):341-8. PubMed ID: 19637098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
    Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Barrera Ramírez C; Sabaté M; Fernandez C; Hernández-Antolín R; Escaned J; Alfonso F; Macaya C
    J Invasive Cardiol; 2004 Apr; 16(4):169-74. PubMed ID: 15152138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.